Search
Saturday 20 June 2015
  • :
  • :

Current Trade Stocks Roundup: Two Harbors Investment (NYSE:TWO), Norfolk Southern (NYSE:NSC), Immunomedics, (NASDAQ:IMMU), Zulily (NASDAQ:ZU)

During Friday’s current trade, Two Harbors Investment Corp (NYSE:TWO)’s shares incline 0.05% to $10.48.

Two Harbors Investment Corp (TWO) declared a quarterly dividend of $0.26 per share of common stock for the second quarter of 2015. This dividend is payable on July 21, 2015 to common stockholders of record at the close of business on June 30, 2015.

Two Harbors distributes dividends based on its current estimate of taxable earnings per common share, not GAAP earnings. Taxable and GAAP earnings are predictable to differ principally because of differences in discount accretion and premium amortization, certain non-taxable unrealized and realized gain and losses on derivatives, and non-deductible general and administrative expenses.

Two Harbors Investment Corp. operates as a real estate investment trust (REIT) that focuses on investing in, financing, and managing residential mortgage-backed securities (RMBS), residential mortgage loans, mortgage servicing rights, commercial real estate debt and related assets, and other financial assets.

Norfolk Southern Corp. (NYSE:NSC)‘s shares drop -0.01% to $92.95, during the current trading session Friday’s, hitting its highest level.

Norfolk Southern (NSC) in a ceremony at Washington, D.C.’s Union Station unveiled its latest commemorative locomotive, vibrant SD60E honoring emergency first responders. The locomotive – with insignia recognizing police, fire, and emergency services – will enter general revenue service on Norfolk Southern’s 22-state network.

he red, white, and gold locomotive – its paint scheme designed by NS’ Visual Communications team and painted at the company’s Juniata Locomotive Shop in Altoona, Pa. – features the Maltese Cross of fire services, the Emergency Medical Services’ “Star of Life,” and the Police shield. It also features the logo for Transportation Community Awareness and Emergency Response (TRANSCAER), a national outreach organization dedicated to providing education and resources to assist raise the level of emergency preparedness for the unlikely event of a rail incident. The locomotive sports “9-1-1,” the phone number to request emergency assistance, in addition to the Norfolk Southern OAR shield.

Norfolk Southern Corporation, together with its auxiliaries, engages in the rail transportation of raw materials, intermediate products, and finished goods. As of December 31, 2014, it operated about 20,000 miles of road in 22 states and the District of Columbia. The company also operates planned passenger trains; transports overseas freight through various Atlantic and Gulf Coast ports; and provides logistics services. In addition, it provides bimodal truckload transportation services primarily utilizing RoadRailer trailers, a hybrid technology that facilitates over-the-road and on-the-rail transportation in the eastern United States, in addition to in Ontario and Quebec through a network of terminals.

In a mid-morning trade, Immunomedics, Inc. (NASDAQ:IMMU)‘s shares plunge -3.82% to $4.28.

Immunomedics, Inc. (IMMU) declared an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate (ADC), labetuzumab govitecan, produced encouraging survival results in patients formerly treated with at least one prior irinotecan-containing regimen for their metastatic colorectal cancer (mCRC).

For the 33 patients who received the ADC at the 8 or 10 mg/kg dose levels, the interim median progression-free survival (PFS), a measure of the length of time the patient is living without their disease getting worse from the starting of their labetuzumab govitecan treatments, was 4.4 months, with 22% of these patients still benefiting from their cancer not progressing.

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs comprise epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer.

Zulily Inc (NASDAQ:ZU), during its Friday’s current trading session -3.57% loss and closed at $14.44.

Zulily Inc (ZU) was founded five years ago and brought a lot of attention — and wealth — to the region as the online retailer took off and its stock popped. In February 2014, the stock price even crested $72 a share.

But for more than a year now, those early investors have been stuck riding the company’s ups and downs.

Revenue isn’t growing as fast as some investors predictable and one analyst even apologized for ever recommending the company.

That may come as a surprise to people here in the Puget Sound region who has watched the company grow. Zulily was Washington’s fastest-growing public company last year when measured by revenue, one of the first times a retailer has topped that list. Zulily’s revenue raised 262 percent between 2012 and 2014, and hit $1 billion last year.

zulily, inc. operates as an online retailer in the United States, Canada, Australia, the United Kingdom, and internationally. The company provides merchandise to moms purchasing for their children, themselves, and their homes. Its merchandise comprises men’s, women’s, and children’s apparel, accessories, and shoes; children’s merchandise, such as infant gear, sports equipment, toys, and books; and other merchandise comprising kitchen accessories, home décor, entertainment, electronics, pet accessories, and health and beauty products.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

 




Leave a Reply

Your email address will not be published. Required fields are marked *